

# Michelle L O donoghue

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6541034/michelle-l-odonoghue-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

3,951

citations

30

h-index

62

g-index

72

ext. papers

5,166

ext. citations

10.8

avg, IF

4.91

L-index

#	Paper	IF	Citations
62	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet, The</i> , <b>2009</b> , 374, 989-997	40	531
61	Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 71-80	27.4	314
60	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , <b>2019</b> , 139, 1483-1492	16.7	288
59	Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 1006-15	27.4	285
58	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , <b>2019</b> , 51, 957-972	36.3	217
57	Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. <i>Circulation</i> , <b>2006</b> , 113, 1745-52	16.7	192
56	Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. <i>Circulation</i> , <b>2006</b> , 114, 550-7	16.7	148
55	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1591-9	27.4	144
54	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , <b>2020</b> , 11, 163	17.4	140
53	Safety and tolerability of atropaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin. <i>Acute Coronary Syndromes Trial. Circulation</i> , <b>2011</b> , 123, 1843-53	16.7	130
52	Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2349-2359	15.1	126
51	Lipoprotein(a) for risk assessment in patients with established coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 520-7	15.1	119
50	The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. <i>Journal of the American College of</i>	15.1	94
49	Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. <i>Circulation</i> , <b>2006</b> , 114, e600-6	16.7	93
48	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. <i>Circulation</i> , <b>2019</b> , 140, 1308-1317	16.7	85
47	Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	76
46	An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 106-11	15.1	69

45	Study design and rationale for the Stabilization of pLaques using Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. <i>American Heart Journal</i> , <b>2011</b> , 162, 613-619.e1	4.9	69
44	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , <b>2016</b> , 99, 40-55	11	61
43	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 899-911	18.1	61
42	Natriuretic peptides in heart failure: should therapy be guided by BNP levels?. <i>Nature Reviews Cardiology</i> , <b>2010</b> , 7, 13-20	14.8	53
41	The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Circulation</i> , <b>2020</b> , 142, 538-545	16.7	52
40	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , <b>2016</b> , 99, 8-21	11	47
39	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , <b>2016</b> , 99, 22-39	11	42
38	Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. <i>European Heart Journal</i> , <b>2015</b> , 36, 1470-7	9.5	42
37	Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. <i>European Heart Journal</i> , <b>2008</b> , 29, 984-91	9.5	40
36	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 1549-1559	15.1	36
35	The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. <i>International Journal of Cardiology</i> , <b>2018</b> , 270, 245-252	3.2	34
34	The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. <i>Circulation</i> , <b>2020</b> , 141, 1600-1607	16.7	32
33	Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). <i>JACC: Cardiovascular Interventions</i> , <b>2013</b> , 6, 1275-81	5	31
32	Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 3013-3022	15.1	30
31	Rationale and design of the Losmapimod To Inhibit p38 MAP kinase as a Therapeutic target and modify outcomes after an acute coronary syndrome trial. <i>American Heart Journal</i> , <b>2015</b> , 169, 622-630.e6	4.9	27
30	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 709-713	16.2	25
29	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. <i>Circulation</i> , <b>2016</b> , 133, 248-55	16.7	23
28	Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 473-480	16.2	21

27	Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. <i>European Heart Journal</i> , <b>2018</b> , 39, 3810-3820	9.5	18
26	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2012</b> , 34, 36-43	5.1	14
25	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , <b>2021</b> , 143, 470-478	16.7	13
24	The future of biomarkers in the management of patients with acute coronary syndromes. <i>Current Opinion in Cardiology</i> , <b>2008</b> , 23, 309-14	2.1	12
23	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182115	3.7	10
22	Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 737-751	15.1	10
21	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 1512-1518	9.9	9
20	Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1311-7	5.5	8
19	Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017401	6	6
18	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 353-360	5.1	6
17	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , <b>2021</b> , 99, 926-939	9.9	6
16	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	5
15	Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 130-2	14.8	5
14	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> ,	3.9	5
13	Antiplatelet therapy after percutaneous coronary intervention.. <i>EuroIntervention</i> , <b>2022</b> , 17, e1371-e1396	5.1	5
12	Soluble interleukin-13r $\alpha$ 2: a circulating regulator of glucose. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2017</b> , 313, E663-E671	6	4
11	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2021</b> , 64, 1226-1234	10.3	4
10	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 675-681	5.1	3

9	Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. <i>Circulation</i> , <b>2021</b> , 143, 685-695	16.7	3
8	Women and Heart Attacks. <i>Circulation</i> , <b>2016</b> , 133, e428-9	16.7	2
7	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , <b>2021</b> , 143, 673-684	16.7	2
6	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204352	3.7	2
5	Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2006</b> , 8, 3-11	2.1	1
4	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
3	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , <b>2022</b> , 243, 147-157	4.9	1
2	Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And Lipoprotein(a) reduction-DOSE Finding Study) Trial.. <i>American Heart Journal</i> , <b>2022</b> , 251, 61-61	4.9	1
1	Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUTcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study.. <i>Thrombosis Research</i> , <b>2022</b> , 214, 122-131	8.2	0